Janus Henderson Group PLC Increases Stake in Zai Lab Limited (NASDAQ:ZLAB)

Janus Henderson Group PLC raised its holdings in shares of Zai Lab Limited (NASDAQ:ZLAB) by 34.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,760,074 shares of the company’s stock after purchasing an additional 2,232,507 shares during the quarter. Janus Henderson Group PLC owned approximately 8.79% of Zai Lab worth $211,488,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its stake in shares of Zai Lab by 58.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,559 shares of the company’s stock valued at $231,000 after buying an additional 3,514 shares in the last quarter. Daiwa Securities Group Inc. raised its holdings in Zai Lab by 4,851.8% during the 3rd quarter. Daiwa Securities Group Inc. now owns 9,557 shares of the company’s stock valued at $231,000 after acquiring an additional 9,364 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Zai Lab during the second quarter worth $270,000. Tidal Investments LLC bought a new position in shares of Zai Lab in the first quarter worth $334,000. Finally, Erste Asset Management GmbH bought a new position in shares of Zai Lab in the third quarter worth $357,000. Institutional investors own 41.65% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Zai Lab in a report on Friday, October 25th. JPMorgan Chase & Co. upped their price target on Zai Lab from $38.00 to $44.00 and gave the company an “overweight” rating in a research report on Monday, October 21st.

Zai Lab Stock Performance

Zai Lab stock opened at $30.16 on Wednesday. The stock has a market cap of $3.28 billion, a P/E ratio of -10.89 and a beta of 0.99. Zai Lab Limited has a fifty-two week low of $13.48 and a fifty-two week high of $36.60. The firm’s fifty day moving average price is $27.64 and its 200-day moving average price is $21.86.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.